Last reviewed · How we verify
gp140 HIV Bivalent Vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
gp140 HIV Bivalent Vaccine (gp140 HIV Bivalent Vaccine) — Janssen Vaccines & Prevention B.V..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| gp140 HIV Bivalent Vaccine TARGET | gp140 HIV Bivalent Vaccine | Janssen Vaccines & Prevention B.V. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- gp140 HIV Bivalent Vaccine CI watch — RSS
- gp140 HIV Bivalent Vaccine CI watch — Atom
- gp140 HIV Bivalent Vaccine CI watch — JSON
- gp140 HIV Bivalent Vaccine alone — RSS
Cite this brief
Drug Landscape (2026). gp140 HIV Bivalent Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/gp140-hiv-bivalent-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab